Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab in moderate to severe atopic dermatitis
NCT03747575Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of astegolimab in atopic dermatitis (AD), sponsored by Genentech. Started Feb 2019; status: completed.
02
Drugs
astegolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03747575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747575.